Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 7/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729609 | 1.00 | KCNH2 (0.45) | KCNH2KDM4EPOLBPRKD3ALDH1A1 | |
| SCHEMBL727962 | 0.92 | KCNH2 (0.38) | KCNH2KDM4EPOLBPRKD3ALDH1A1 | |
| SCHEMBL727961 | 0.92 | KCNH2 (0.38) | KCNH2KDM4EPOLBPRKD3ALDH1A1 | |
| SCHEMBL536995 | 0.91 | KCNH2 (0.49) | KCNH2KDM4EPOLBPRKD3ALDH1A1 | |
| SCHEMBL728232 | 0.89 | KCNH2 (0.46) | KCNH2KDM4EPOLBPRKD3ALDH1A1 | |
| SCHEMBL728233 | 0.89 | KCNH2 (0.46) | KCNH2KDM4EPOLBPRKD3ALDH1A1 | |
| SCHEMBL15077883 | 0.89 | KCNH2 (0.45) | KCNH2KDM4EPOLBPRKD3ALDH1A1 | |
| SCHEMBL729663 | 0.88 | KCNH2 (0.59) | KCNH2KDM4EPOLBPRKD3ALDH1A1 | |
| SCHEMBL729664 | 0.88 | KCNH2 (0.59) | KCNH2KDM4EPOLBPRKD3ALDH1A1 | |
| SCHEMBL15078149 | 0.86 | KCNH2 (0.40) | KCNH2KDM4EPOLBPRKD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138346-B2 | Method for synthesis of 8-alkoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138346-B2 | Method for synthesis of 8-alkoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138346-B2 | Method for synthesis of 8-alkoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110213152-A1 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110213152-A1 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110213152-A1 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7902365-B2 | Using a 2-sulfone, 3-carboxylate, 4-oxoquinoline as chemical intermediate ; cyclization | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902365-B2 | Using a 2-sulfone, 3-carboxylate, 4-oxoquinoline as chemical intermediate ; cyclization | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902365-B2 | Using a 2-sulfone, 3-carboxylate, 4-oxoquinoline as chemical intermediate ; cyclization | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080071086-A1 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080071086-A1 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080071086-A1 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2008021491-A2 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213152-A1 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES | QDPR, CYP4B1, DRD4 | KCNH2 76/4885KDM4E 573/4885POLB 1123/4885 |
| US-20080071086-A1 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES | QDPR, CYP4B1, DRD4 | KCNH2 76/4885KDM4E 573/4885POLB 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.